Crescent Biopharma, Inc. (CBIO)
| Market Cap | 796.17M |
| Revenue (ttm) | 10.84M |
| Net Income (ttm) | -153.94M |
| Shares Out | 33.23M |
| EPS (ttm) | -12.81 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,355 |
| Open | 24.84 |
| Previous Close | 25.15 |
| Day's Range | 23.76 - 25.10 |
| 52-Week Range | 8.72 - 27.41 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 26.67 (+11.31%) |
| Earnings Date | May 23, 2026 |
About CBIO
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is head... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CBIO stock is "Strong Buy." The 12-month stock price target is $26.67, which is an increase of 11.31% from the latest price.
News
Crescent Biopharma Announces Grants of Inducement Awards
WALTHAM, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next...
Crescent Biopharma Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified oncology portfolio, highlighted by a PD-1/VEGF bispecific and multiple ADCs, with a strategic partnership enabling parallel data generation in China and globally. Key clinical readouts are expected in 2027, supported by strong funding and a focus on best-in-class differentiation.
Crescent Biopharma Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a robust oncology pipeline, highlighted by CR-001 and strategic ADC assets, with multiple studies launching and key data readouts expected in 2027. Strong partnerships and financial position support a data-driven, combination-focused development strategy.
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs
Crescent Biopharma to Present at March Investor Conferences
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patient...
Crescent Biopharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
A robust oncology portfolio is advancing with global clinical trials for CR-001 and differentiated ADCs, supported by a strong financial position and strategic partnerships. Key data readouts are expected from 2027, with combination studies and industry catalysts shaping future development.
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next ...
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
CR-001 IND cleared by U.S. FDA; Phase 1/2 ASCEND global clinical trial to evaluate CR-001 in first-line and previously treated patients on track to initiate in first quarter of 2026, with proof-of-con...
Crescent Biopharma Transcript: Partnership
A strategic partnership with Kelun-Biotech accelerates development of IO and ADC therapies, enabling parallel clinical trials in the US, Europe, and China. Four clinical trials are set for 2026, with multiple data readouts expected in 2027, supported by a $185M capital raise.
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
Partnership with Kelun-Biotech expands pipeline and accelerates combination strategy with CR-001, a PD-1 x VEGF bispecific antibody, and multiple antibody-drug conjugates (ADCs), generating clinical d...
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
Companies to advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in global markets and China
Crescent Biopharma Transcript: Jefferies London Healthcare Conference 2025
A dual strategy centers on CR001 (PD-1 VEGF bispecific) and an ADC pipeline, with global phase I trials for CR001 starting soon and CR002 to follow. The company leverages industry data, aims for rapid clinical expansion, and is well-funded through 2027.
Crescent Biopharma Transcript: Stifel 2025 Healthcare Conference
Management outlined a dual strategy focused on a next-gen IO backbone (CR-001) and best-in-class ADC combinations, with CR-001 entering clinical trials soon and proof-of-concept data expected by late 2026 or early 2027. The company is well-capitalized, leveraging robust preclinical data and global trial design to accelerate development and de-risk programs.
Crescent Biopharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
A dual strategy is being pursued with a PD1 VEGF bispecific and ADC pipeline, targeting robust clinical development and differentiation in a competitive oncology market. Phase I trials for CR001 will begin early next year, with strong financial runway through 2027 and a focus on high-quality data to drive partnerships and expansion.
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
IND Submission for CR-001, a PD-1 x VEGF Bispecific Antibody, on Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors Advancing ADCs in the Pip...
Crescent Biopharma to Present at November Investor Conferences
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapi...
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients wit...
Crescent Biopharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
A dual immuno-oncology and ADC strategy is driving rapid clinical development, with CR-001 set for first patient dosing in Q1 2026 and key data expected by early 2027. Strong validation from recent industry data, robust cash runway, and a focus on global expansion position the company for leadership in the bi-specific and ADC space.
Crescent Biopharma Transcript: Cantor Global Healthcare Conference 2025
Focused on building a leading oncology franchise, the company is advancing a VEGF/PD-1 bispecific antibody (CR-001) and ADC programs, with global clinical trials and a strong cash runway through 2027. The strategy leverages proven structures, aims for differentiation, and maintains flexibility for partnerships.
Crescent Biopharma to Present at September Investor Conferences
WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapi...
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
Advancing Lead Program, CR-001, a PD-1 x VEGF Bispecific Antibody, and Developing Pipeline of Novel ADCs as Single Agents and in Combination with CR-001
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, In...